DOCSLIB.ORG

Structural Studies on Phenylalanine Hydroxylase and Implications Toward Understanding and Treating Phenylketonuria

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structural Studies on Phenylalanine Hydroxylase and Implications Toward Understanding and Treating Phenylketonuria Structural Studies on Phenylalanine Hydroxylase and Implications Toward Understanding and Treating Phenylketonuria Heidi Erlandsen, DrSci; Marianne G. Patch, PhD; Alejandra Gamez, PhD; Mary Straub; and Raymond C. Stevens, PhD ABSTRACT. Mutations in the gene encoding for phe- discusses some of the structural effects of the cur- nylalanine hydroxylase (PAH) result in phenylketonuria rently known mutations in the PAH gene, including (PKU) or hyperphenylalaninemia (HPA). Several 3-di- some of the BH4-responsive PKU/HPA mutations mensional structures of truncated forms of PAH have (PKU database at www.pahdb.mcgill.ca and PAH been determined in our laboratory and by others, using Mutation Analysis Consortium Newsletter, Decem- x-ray crystallographic techniques. These structures have allowed for a detailed mapping of the >250 missense ber 2001). mutations known to cause PKU or HPA found through- Human (liver) PAH (EC. 1.14.16.1) exists in a pH- out the 3 domains of PAH. This structural information dependent equilibrium of homotetramers and ho- has helped formulate rules that might aid in predicting modimers,7 and, like the 2 other aromatic amino acid the likely effects of unclassified or newly discovered hydroxylases tyrosine hydroxylase (EC 1.14.16.2) PAH mutations. Also, with the aid of recent crystal struc- and tryptophan hydroxylase (EC 1.14.16.4), consists ture determinations of co-factor and substrate analogs of 3 domains: an N-terminal regulatory domain (res- bound at the PAH active site, the recently discovered idues 1–142), a catalytic domain (residues 143–410), tetrahydrobiopterin-responsive PKU/HPA genotypes can be mapped onto the PAH structure, providing a molecu- and a C-terminal tetramerization domain (residues lar basis for this tetrahydrobiopterin response. Pediatrics 411- 452; Fig 1). Because of the difficulty of crystal- 2003;112:1557–1565; phenylalanine hydroxylase, 3-dimen- lizing full-length PAH, no full-length tetrameric sional structure, structural basis, phenylketonuria, BH4- structures exist for PAH. However, several truncated responsive hyperphenylalaninemia, co-factor therapy. forms of PAH have been structurally characterized, including a dimeric form containing the regulatory 3 ABBREVIATIONS. PAH, phenylalanine hydroxylase; l-Phe, l- and catalytic domains and a tetrameric form con- 2 phenylalanine; BH4, tetrahydrobiopterin; PKU, phenylketonuria; taining the catalytic and tetramerization domains. HPA, hyperphenylalaninemia; ARS, autoregulatory sequence; On the basis of these structures and a higher-resolu- CBR, co-factor–binding region. tion dimeric double-truncated form of PAH,1 a com- posite full-length structural model was constructed uman phenylalanine hydroxylase (PAH) by superimposing the respective catalytic domain converts the essential amino acid l-phenyl- regions (Figs 2–4).8 alanine (l-Phe) into l-tyrosine using the The regulatory domain of PAH contains an ␣-␤ H sandwich with an interlocking double ␤␣␤ motif co-factor (6R)-l-erythro-5,6,7,8-tetrahydrobiopterin ␤␣␤␤␣␤ 3 (BH4) and molecular oxygen. Catalysis by this iron- ( topology) (Fig 4). The N-terminal autoreg- dependent enzyme is the major pathway for cata- ulatory sequence (ARS; residues 19–33) extends over bolic degradation of dietary l-Phe and accounts for the active site in the catalytic domain. approximately 75% of the l-Phe disposal. The auto- An N-terminal truncated form of PAH that in- somal recessive disorder phenylketonuria (PKU) is cludes the catalytic and tetramerization domains the result of a deficiency of PAH enzymatic activity (residues 116–452) crystallized as a tetramer (dimer or loss of enzyme expression as a result of mutations of dimers).2 The tetramerization domain contains 2 in the PAH gene. Because of extensive newborn ␤-strands, forming a ␤-ribbon, and a 40-Å-long ␣-he- screening for PKU and genotyping of the PAH al- lix.2,9 The 4 ␣-helices (1 from each monomer) pack leles, Ͼ400 mutations in the PAH gene are known to into a tight antiparallel coiled-coil motif in the center cause PKU or the milder form referred to as hyper- of the tetramer structure (Fig 4). phenylalaninemia (HPA). The recently solved crystal Recombinant double-truncated human PAH 1–6 ⌬ ⌬ structures of PAH provide a structural scaffold to ( NH102- COOH428, hPAHCat) represents a fully explain the effects of PAH mutations. This review activated form of the enzyme, without any cooper- covers the structural work done so far on PAH and ativity of l-Phe binding.10 Thus, this structure repre- sents the activated, or R state, of PAH. The catalytic From the Department of Molecular Biology, Scripps Research Institute, La domain region of the PAH structure (hPAHCat) has a Jolla, California. basket-like arrangement, with a total of 13 ␣-helices Reprint requests (R.C.S.) to Department of Molecular Biology, Scripps Re- and 8 ␤-strands. Because part of the C-terminal tet- search Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037. E-mail: ramerization domain is missing, this double-trun- [email protected] PEDIATRICS (ISSN 0031 4005). Copyright © 2003 by the American Acad- cated PAH construct forms a dimer in solution, as emy of Pediatrics. well as in the crystal. Downloaded from www.aappublications.org/news PEDIATRICSby guest on September Vol. 11225, 2021 No. 6 December 2003 1557 Fig 1. Scheme showing the secondary structure assignment of human PAH sequence (SWISS-PROT P00439). Sec- ondary structure was assigned using the program DSSP56 on the composite PAH model.8 Residues that have PKU mutations associated with them are marked with grey dots. Secondary structural elements of the 3 regulatory domain are indicated as arrows for ␤-strands and coils for ␣-helical re- gions. Reprinted with permission from Erlandsen and Stevens.49 Fig 2. Bar graph showing the trunca- tions made in PAH to form crystals. The figure contains information about the oligomeric state of the protein along with the resolution of the crystal structures. The active site, located in the center of the catalytic on the “floor” of the active site, at the intersection of domain, consists of a 13-Å-deep and 10-Å-wide the channel and the active site pocket. The Fe(III) pocket (Fig 3).1 Adjacent to the active site is a 16-Å- atom is coordinated to His285, His290, and 1 oxygen long and 8-Å-wide channel that may provide sub- atom in Glu330. Both His285 and His290 have been strate access to the active site. The majority of the 34 shown by site-directed mutagenesis to be required amino acids lining the active site are hydrophobic, for iron binding.12 Well-defined electron density is but 3 charged glutamates, 2 histidines, and 1 tyrosine also observed for 3 water molecules coordinated to are also located in this region. Covering the entrance the iron. The iron ligands are arranged in an octahe- to the active site is a short loop (residues 378–381) dral geometry, making the iron 6-coordinate as pre- that contains some of the highest B-factors in the viously suggested from spectroscopic studies.13 structure (60–80 Å2), indicative of a flexible, or dis- The PAH hydroxylation reaction requires the ordered, loop region. binding of BH4, dioxygen, and Fe(II) before hydroxy- As isolated, the PAH protein contains an active site lation of l-Phe can occur. A stretch of 27 PAH amino Fe(III) atom.1,11 In the crystal structures, the iron acids (His263 to His289), which is highly conserved atom is located 10 Å below the surface of the protein in all 3 aromatic amino acid hydroxylases, was 1558 STUDIES ON PAHDownloaded AND UNDERSTANDING from www.aappublications.org/news AND TREATING by guest PKUon September 25, 2021 with Phe254, and the pterin ring and dihydroxypro- pyl side-chain are positioned by a Tyr325 hydropho- bic interaction. The BH2 dihydroxypropyl side chain O2Ј atom hydrogen bonds to the carbonyl oxygen of Ala322, and Glu286 hydrogen bonds to 1 of the water molecules coordinated to the iron and also hydrogen bonds to a water molecule that is hydrogen bonded to the N3 position of the pterin ring. In addition, a major conformational change occurs in the active site upon pterin binding; residues 245 to 250 move in the direction of the iron, allowing several protein hydro- gen bonds to the pterin ring to be formed. Bound pterin co-factor is in an ideal location for dioxygen binding in a bridging position between the iron and the pterin, as is presumed to happen during the l-Phe hydroxylation reaction. Fig 3. Structure of a monomer of human PAH full-length com- posite model. The regulatory domain (residues 19–142), the cata- Although several alternative co-factor analogs are lytic domain (residues 143–410), and the tetramerization domain capable of being used in the PAH hydroxylation comprise the full-length monomer. The active site iron is shown as reaction, only the natural co-factor (BH4) inhibits the a sphere. Reprinted with permission from Erlandsen and Stevens.8 l-Phe induced activation of the enzyme13; the molec- ular mechanism of this inhibition is not yet under- 3,13,16 thought to be responsible for tetrahydrobiopterin stood. BH2 inhibits the activation by l-Phe less 14,15 17 binding before any structures were known. In the than the inhibition observed with BH4. Hydrogen PAH structures, 10 residues (Phe263, Cys265, bonding between the pterin dihydroxypropyl side Thr266, Thr278, Pro279, Glu280, Pro281, His285, chain and the carbonyl oxygen of Ala322, in combi- Glu286, and Gly289) in this co-factor–binding motif nation with the PAH loop 245 to 250 conformational are present in the active site. changes observed on co-factor binding, could pro- Based on co-crystal structures of double-truncated vide a specific regulatory function of the pterin upon Fe(III)-containing human PAH with oxidized co- binding at the active site. It is interesting that when ⅐ ⅐ factor (hPAHCat 7,8-BH2) or Fe(II)-containing hu- the binary complex hPAHCat 7,8-BH2 structure is man PAH with reduced (natural) co-factor superimposed onto the structure of the ligand-free ⅐ 5 (hPAHCat BH4), structural details of co-factor bind- C-terminal truncated rat PAH (rPAHReg containing 3 ing have been determined.
Load more

Recommended publications
  • Monoamine Oxydases Et Athérosclérose : Signalisation Mitogène Et Études in Vivo
    UNIVERSITE TOULOUSE III - PAUL SABATIER Sciences THESE Pour obtenir le grade de DOCTEUR DE L’UNIVERSITE TOULOUSE III Discipline : Innovation Pharmacologique Présentée et soutenue par : Christelle Coatrieux le 08 octobre 2007 Monoamine oxydases et athérosclérose : signalisation mitogène et études in vivo Jury Monsieur Luc Rochette Rapporteur Professeur, Université de Bourgogne, Dijon Monsieur Ramaroson Andriantsitohaina Rapporteur Directeur de Recherche, INSERM, Angers Monsieur Philippe Valet Président Professeur, Université Paul Sabatier, Toulouse III Madame Nathalie Augé Examinateur Chargé de Recherche, INSERM Monsieur Angelo Parini Directeur de Thèse Professeur, Université Paul Sabatier, Toulouse III INSERM, U858, équipes 6/10, Institut Louis Bugnard, CHU Rangueil, Toulouse Résumé Les espèces réactives de l’oxygène (EROs) sont impliquées dans l’activation de nombreuses voies de signalisation cellulaires, conduisant à différentes réponses comme la prolifération. Les EROs, à cause du stress oxydant qu’elles génèrent, sont impliquées dans de nombreuses pathologies, notamment l’athérosclérose. Les monoamine oxydases (MAOs) sont deux flavoenzymes responsables de la dégradation des catécholamines et des amines biogènes comme la sérotonine ; elles sont une source importante d’EROs. Il a été montré qu’elles peuvent être impliquées dans la prolifération cellulaire ou l’apoptose du fait du stress oxydant qu’elles génèrent. Ce travail de thèse a montré que la MAO-A, en dégradant son substrat (sérotonine ou tyramine), active une voie de signalisation mitogène particulière : la voie métalloprotéase- 2/sphingolipides (MMP2/sphingolipides), et contribue à la prolifération de cellules musculaire lisses vasculaires induite par ces monoamines. De plus, une étude complémentaire a confirmé l’importance des EROs comme stimulus mitogène (utilisation de peroxyde d’hydrogène exogène), et a décrit plus spécifiquement les étapes en amont de l’activation de MMP2, ainsi que l’activation par la MMP2 de la sphingomyélinase neutre (première enzyme de la cascade des sphingolipides).
    [Show full text]
  • Targeting the Tryptophan Hydroxylase 2 Gene for Functional Analysis in Mice and Serotonergic Differentiation of Embryonic Stem Cells
    TARGETING THE TRYPTOPHAN HYDROXYLASE 2 GENE FOR FUNCTIONAL ANALYSIS IN MICE AND SEROTONERGIC DIFFERENTIATION OF EMBRYONIC STEM CELLS Inaugural-Dissertation to obtain the academic degree Doctor rerum naturalium (Dr. rer. nat.) submitted to the Department of Biology, Chemistry and Pharmacy of Freie Universität Berlin by Dana Kikic, M.Sc. in Molecular biology and Physiology from Nis June, 2009 The doctorate studies were performed in the research group of Prof. Michael Bader Molecular Biology of Peptide Hormones at Max-Delbrück-Center for Molecular Medicine in Berlin, Buch Mai 2005 - September 2008. 1st Reviewer: Prof. Michael Bader 2nd Reviewer: Prof. Udo Heinemann date of defence: 13. August 2009 ACKNOWLEDGMENTS Herewith, I would like to acknowledge the persons who made this thesis possible and without whom my initiation in the world of basic science research would not have the spin it has now, neither would my scientific illiteracy get the chance to eradicate. I am expressing my very personal gratitude and recognition to: Prof. Michael Bader, for an inexhaustible guidance in all the matters arising during the course of scientific work, for an instinct in defining and following the intellectual challenge and for letting me following my own, for necessary financial support, for defining the borders of reasonable and unreasonable, for an invaluable time and patience, and an amazing efficiency in supporting, motivating, reading, correcting and shaping my scientific language during the last four years. Prof. Harald Saumweber and Prof. Udo Heinemann, for taking over the academic supervision of the thesis, and for breathing in it a life outside the laboratory walls and their personal signature.
    [Show full text]
  • Molecule of the Month: Phenylalanine Hydroxylase
    Molecule of the Month: Phenylalanine Hydroxylase An unusual cofactor is used in the synthesis of aromatic amino acids The Protein Alphabet The proteins that make up the skin, muscle, hair, bones and other organs in your body are primarily composed of a set of 20 building blocks, called amino acids. Amino acids are the alphabet in the protein language: when combined in a specific order, they make up meaningful structures (proteins) with varied and specific functions. Amino acids have distinct shapes, sizes, charges and other characteristics. Many amino acids are synthesized in your body from breakdown products of sugars and fats, or are converted from other amino acids by the action of specific enzymes. However, a few of them, called essential amino acids, cannot be synthesized or converted in your body and have to be obtained from the food you eat. Phenylalanine is one such essential amino acid. It is closely related to another amino acid, tyrosine, which just has an additional hydroxyl (OH) group. Liver cells contain an enzyme called phenylalanine hydroxylase, which can add this group and convert phenylalanine to tyrosine. Thus as long as this enzyme is functional and there is a reasonable supply of phenylalanine, tyrosine can be synthesized in your body and does not have to be included in the food that you eat. Phenylalanine Hydroxylase Four molecules of phenylalanine hydroxylase interact to form a tetramer, which is the functional unit for this enzyme. Each molecule in the tetramer is organized into three domains: a regulatory domain, a catalytic domain where the enzyme activity resides and a tetramerization domain that assembles four chains into the tetramer.
    [Show full text]
  • Drug-Induced Movement Disorders
    Medical Management of Early PD Samer D. Tabbal, M.D. May 2016 Associate Professor of Neurology Director of The Parkinson Disease & Other Movement Disorders Program Mobile: +961 70 65 89 85 email: [email protected] Conflict of Interest Statement No drug company pays me any money Outline So, you diagnosed Parkinson disease .Natural history of the disease .When to start drug therapy? .Which drug to use first for symptomatic treatment? ● Levodopa vs dopamine agonist vs MAOI Natural History of Parkinson Disease Before levodopa: Death within 10 years After levodopa: . “Honeymoon” period (~ 5-7 years) . Motor (ON/OFF) fluctuations & dyskinesias: ● Drug therapy effective initially ● Surgical intervention by 10-15 years - Deep brain stimulation (DBS) therapy Motor Response Dyskinesia 5-7 yrs >10 yrs Dyskinesia ON state ON state OFF state OFF state time time Several days Several hours 1-2 hour Natural History of Parkinson Disease Prominent gait impairment and autonomic symptoms by 20-25 years (Merola 2011) Behavioral changes before or with motor symptoms: . Sleep disorders . Depression . Anxiety . Hallucinations, paranoid delusions Dementia at anytime during the illness . When prominent or early: diffuse Lewy body disease Symptoms of Parkinson Disease Motor Symptoms Sensory Symptoms Mental Symptoms: . Cognitive and psychiatric Autonomic Symptoms Presenting Symptoms of Parkinson Disease Mood disorders: depression and lack of motivation Sleep disorders: “acting out dreams” and nightmares Early motor symptoms: Typically Unilateral . Rest tremor: chin, arms or legs or “inner tremor” . Bradykinesia: focal and generalized slowness . Rigidity: “muscle stiffness or ache” Also: (usually no early postural instability) . Facial masking with hypophonia: “does not smile anymore” or “looks unhappy all the time” .
    [Show full text]
  • The Neurochemical Consequences of Aromatic L-Amino Acid Decarboxylase Deficiency
    The neurochemical consequences of aromatic L-amino acid decarboxylase deficiency Submitted By: George Francis Gray Allen Department of Molecular Neuroscience UCL Institute of Neurology Queen Square, London Submitted November 2010 Funded by the AADC Research Trust, UK Thesis submitted for the degree of Doctor of Philosophy, University College London (UCL) 1 I, George Allen confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signed………………………………………………….Date…………………………… 2 Abstract Aromatic L-amino acid decarboxylase (AADC) catalyses the conversion of 5- hydroxytryptophan (5-HTP) and L-3,4-dihydroxyphenylalanine (L-dopa) to the neurotransmitters serotonin and dopamine respectively. The inherited disorder AADC deficiency leads to a severe deficit of serotonin and dopamine as well as an accumulation of 5-HTP and L-dopa. This thesis investigated the potential role of 5- HTP/L-dopa accumulation in the pathogenesis of AADC deficiency. Treatment of human neuroblastoma cells with L-dopa or dopamine was found to increase intracellular levels of the antioxidant reduced glutathione (GSH). However inhibiting AADC prevented the GSH increase induced by L-dopa. Furthermore dopamine but not L-dopa, increased GSH release from human astrocytoma cells, which do not express AADC activity. GSH release is the first stage of GSH trafficking from astrocytes to neurons. This data indicates dopamine may play a role in controlling brain GSH levels and consequently antioxidant status. The inability of L-dopa to influence GSH concentrations in the absence of AADC or with AADC inhibited indicates GSH trafficking/metabolism may be compromised in AADC deficiency.
    [Show full text]
  • First Structure of Full-Length Mammalian Phenylalanine Hydroxylase Reveals the Architecture of an Autoinhibited Tetramer
    First structure of full-length mammalian phenylalanine hydroxylase reveals the architecture of an autoinhibited tetramer Emilia C. Arturoa,b, Kushol Guptac, Annie Hérouxd, Linda Stitha, Penelope J. Crosse,f,g, Emily J. Parkere,f,g, Patrick J. Lollb, and Eileen K. Jaffea,1 aMolecular Therapeutics, Fox Chase Cancer Center, Temple University Health Systems, Philadelphia, PA 19111; bBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102; cBiochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; dEnergy Sciences Directorate/Photon Science Division, Brookhaven National Laboratory, Upton, NY 11973; eBiomolecular Interaction Centre, University of Canterbury, Christchurch 8041, New Zealand; fDepartment of Chemistry, University of Canterbury, Christchurch 8041, New Zealand; and gMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1142, New Zealand Edited by Judith P. Klinman, University of California, Berkeley, CA, and approved January 21, 2016 (received for review August 27, 2015) Improved understanding of the relationship among structure, dy- There are >500 disease-associated missense variants of human namics, and function for the enzyme phenylalanine hydroxylase PAH; the amino acid substitutions are distributed throughout (PAH) can lead to needed new therapies for phenylketonuria, the the 452-residue protein and among all its domains (Fig. 1A) most common inborn error of amino acid metabolism. PAH is a (7–9). Of those disease-associated variants that have been stud- multidomain homo-multimeric protein whose conformation and ied in vitro (e.g., ref. 10), some confound the allosteric response, multimerization properties respond to allosteric activation by the and some are interpreted as structurally unstable. We also sug- substrate phenylalanine (Phe); the allosteric regulation is neces- gest that the activities of some disease-associated variants may be sary to maintain Phe below neurotoxic levels.
    [Show full text]
  • The Distribution of Tyrosine Hydroxylase-Lmmunoreactive Fibers in Primate Neocortex Is Widespread but Regionally Specific
    The Journal of Neuroscience, January 1987, 7(l): 279-290 The Distribution of Tyrosine Hydroxylase-lmmunoreactive Fibers in Primate Neocortex Is Widespread but Regionally Specific David A. Lewis,lea Michael J. Campbell,’ Stephen L. Foote, I.2 Menek Goldstein,3 and John H. Morrison’ ‘Scripps Clinic and Research Foundation, La Jolla, California 92037, 2Department of Psychiatry, University of California, San Diego, California 92037, and 3N.Y.U. Medical Center, New York, New York 10016 An antiserum directed against tyrosine hydroxylase (TH), an alleled by an elaboration and specialization of the noradrenergic enzyme involved in dopamine and norepinephrine synthe- and serotoninergic projections to neocortex. Compared to rat, sis, was used to visualize axons immunohistochemically in both of these systems in primates exhibit substantial regional monkey n’eocortex. Labeled fibers were distributed through- heterogeneity in the density and laminar distribution of cortical out the entire neocottex, but they had striking patterns of fibers (Brown et al., 1979; Morrison et al., 1982a, b; Takeuchi regional and laminar specialization. For example, primary and Sano, 1983). Midbrain dopaminergic neurons also project motor cortex contained the greatest density of TH-labeled to neocortex, but little is known about the distribution of do- fibers, whereas primary sensory regions were sparsely in- paminergic fibers in primate neocortex. Initial studies on the nervated. Marked heterogeneity of fiber density was also rat revealed that dopaminergic fibers were restricted to limited present among the association regions of the frontal, pari- portions of the prefrontal, cingulate, and perirhinal cortical re- etal, and temporal lobes. In addition, the laminar pattern of gions (Thierry et al., 1973; Berger et al., 1974, 1976; Fuxe et innervation in a given region was correlated with its fiber al., 1974; Hokfelt et al., 1974b; Lindvall et al., 1974).
    [Show full text]
  • Tyrosine Hydroxylase Deficiency in Three Greek Patients with a Common
    1086 R. PONS ET AL. Boston, MA; Jay Gorell, MD (deceased), Shana Krstev- Tyrosine Hydroxylase Deficiency ska, MD: Henry Ford Health System, Detroit, MI; Ryan Uitti, MD, Margaret Turk, RN: Mayo Clinic in Three Greek Patients with a Jacksonville, Jacksonville, FL; James Bower, MD, Common Ancestral Mutation Susan Torgrimson, RN Mayo Clinic Rochester, Roch- ester, MN; Marwan Sabbagh, MD, Zoran Obradov, Roser Pons, MD,1* Mercedes Serrano, MD PhD,2,3 CRC: Sun Health Research Institute, Sun City, AZ. Aida Ormazabal, PhD,2,3 Claudio Toma, PhD,4 Angels Garcia-Cazorla, MD PhD,2,3 Estela Area, PhD,5 Marta Ribase´s, PhD,6 Emmanuel Kanavakis, MD,1 Kaliopi Drakaki, MD,1 Aristotelis Giannakopoulos, MD,1 REFERENCES Irene Orfanou, MD,1 Sotiris Youroukos, MD,1 4 2,3 1. Parkinson Study Group. DATATOP: a multicenter controlled Bru Cormand, PhD, and Rafael Artuch, MD, PhD clinical trial in early Parkinson’s disease. Arch Neurol 1989;46:1052–1060. 1First Department of Pediatrics, Agia Sofia Hospital, 2. NINDS NET-PD Investigators. A randomized clinical trial of University of Athens, Athens, Greece; 2Department of Neuro- coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurol- pediatrics, Sant Joan de De´u Hospital, Center for Biomedical ogy 2007;68:20–28. Research on Rare Diseases (CIBERER), Barcelona, Spain; 3. Tilley BC, Palesch YY, Kieburtz K, et al. Optimizing the 3Department of Clinical Biochemistry, Sant Joan de De´u ongoing search for new treatments for Parkinson disease: using Hospital, Center for Biomedical Research on Rare Diseases futility designs. Neurology 2006;66:628–633. 4 4.
    [Show full text]
  • Gastric Serotonin Biosynthesis and Its Functional Role in L-Arginine-Induced Gastric Proton Secretion
    International Journal of Molecular Sciences Article Gastric Serotonin Biosynthesis and Its Functional Role in L-Arginine-Induced Gastric Proton Secretion Ann-Katrin Holik 1,†, Kerstin Schweiger 1,†, Verena Stoeger 2, Barbara Lieder 1,2 , Angelika Reiner 3, Muhammet Zopun 1, Julia K. Hoi 2, Nicole Kretschy 4, Mark M. Somoza 4,5,6 , Stephan Kriwanek 7, Marc Pignitter 1 and Veronika Somoza 1,2,6,8,* 1 Department of Physiological Chemistry, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (A.-K.H.); [email protected] (K.S.); [email protected] (B.L.); [email protected] (M.Z.); [email protected] (M.P.) 2 Christian Doppler Laboratory for Bioactive Aroma Compounds, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (V.S.); [email protected] (J.K.H.) 3 Pathologisch-Bakteriologisches Institut, Sozialmedizinisches Zentrum Ost- Donauspital, Langobardenstraße 122, 1220 Vienna, Austria; [email protected] 4 Department of Inorganic Chemistry, Faculty of Chemistry, University of Vienna, Althanstraße 14, 1090 Vienna, Austria; [email protected] (N.K.); [email protected] (M.M.S.) 5 Food Chemistry and Molecular Sensory Science, Technical University of Munich, Lise-Meitner-Straße 34, 85354 Freising, Germany 6 Leibniz Institute for Food Systems Biology, Technical University of Munich, Lise-Meitner-Str. 34, 85345 Freising, Germany 7 Chirurgische Abteilung, Sozialmedizinisches Zentrum Ost- Donauspital, Langobardenstraße 122, Citation: Holik, A.-K.; Schweiger, K.; 1220 Vienna, Austria; [email protected] 8 Stoeger, V.; Lieder, B.; Reiner, A.; Nutritional Systems Biology, School of Life Sciences, Technical University of Munich, Lise-Meitner-Str.
    [Show full text]
  • Download Article (PDF)
    CHEMISTRY OF ENZYME INHffiiTORS OF MICROBIAL ORIGIN HAMAO UMEZAWA Institute of Microbial Chemistry and Department of Antibiotics, National Institute of Health, Tokyo, Japan ABSTRACT Study of antibiotics has furnished interesting materials to chemistry of natural products. I initiated the screening study of enzyme inhibitors produced by microorganisms and isolated Ieupeptin and antipain inhibiting trypsin and papain, chymostatin inhibiting chymotrypsin, pepstatin inhibiting pepsin, panosialin inhibiting sialidases, oudenone inhibiting tyrosine hydroxylase, dopastin inhibiting dopamine ß-hydroxylase, aquayamycin and chrothiomycin inhibiting tyrosine hydroxylase and dopamine ß-hydroxylase. Structures and syntheses ofmost ofthese compounds have been studied. I also found dopamine ß-hydroxylase-inhibiting activity of fusaric acid and oosponol, and xanthine­ oxidase inhibiting activity of 5-formyluracil which were produced by micro­ organisms. Chemical study of enzyme inhibitors has given useful information on the structurejactivity relation. The effect of pepstatin on stomach ulcer, and the hypotensive effect of oudenone and fusaric acid have been observed clinically. Enzyme inhibitors produced by microorganisms are the most valuable new area extended from antibiotics and will furnish new materials interesting in chemistry. biosynthesis, pharmacology, and utility. Research on antibiotics has contributed to the chemistry of natural products, furnishing materials of interesting structures, chemical syntheses, biosyntheses and of interesting
    [Show full text]
  • Three Classes of Tetrahydrobiopterin-Dependent Enzymes
    DOI 10.1515/pterid-2013-0003 Pteridines 2013; 24(1): 7–11 Review Ernst R. Werner* Three classes of tetrahydrobiopterin-dependent enzymes Abstract: Current knowledge distinguishes three classes in Antalya, Turkey. For a more detailed review on bio- of tetrahydrobiopterin-dependent enzymes as based on chemistry and pathophysiology of tetrahydrobio pterin, protein sequence similarity. These three protein sequence the reader is referred to Ref. [ 1 ]. Here, a short historical clusters hydroxylate three types of substrate atoms and overview of the discovery of tetrahydrobiopterin-depend- use three different forms of iron for catalysis. The first ent enzymes is presented, followed by a summary of the class to be discovered was the aromatic amino acid biochemical properties of these enzymes. The reactions hydroxylases, which, in mammals, include phenylalanine catalyzed by the three classes of tetrahydrobiopterin- hydroxylase, tyrosine hydroxylase, and two isoforms of dependent enzymes are detailed in Figure 1 . tryptophan hydroxylases. The protein sequences of these tetrahydrobiopterin-dependent aromatic amino acid hydroxylases are significantly similar, and all mammalian Discovery of tetrahydrobiopterin- aromatic amino acid hydroxylases require a non-heme- dependent enzymes bound iron atom in the active site of the enzyme for cataly- sis. The second classes of tetrahydrobiopterin-dependent enzymes to be characterized were the nitric oxide syn- Aromatic amino acid hydroxylases thases, which in mammals occur as three isoforms. Nitric oxide synthase protein sequences form a separate cluster Phenylalanine hydroxylase was the first enzyme charac- of homologous sequences with no similarity to aromatic terized to be dependent on a tetrahydropterin [ 2 ]. It then amino acid hydroxylase protein sequences. In contrast to took five more years to identify the nature of the endo- aromatic amino acid hydroxylases, nitric oxide synthases genous cofactor as tetrahydrobiopterin [ 3 ].
    [Show full text]
  • Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W
    Effects of Alpha-Methyl-Para-Tyrosine- Induced Catecholamine Depletion in Patients with Seasonal Affective Disorder in Summer Remission Raymond W. Lam, M.D., Edwin M. Tam, M.D.C.M., Arvinder Grewal, B.A., and Lakshmi N. Yatham, M.B.B.S. Noradrenergic and dopaminergic mechanisms have been the control diphenhydramine session. The AMPT session proposed for the pathophysiology of seasonal affective resulted in higher depression ratings with all nine patients disorder (SAD). We investigated the effects of having significant clinical relapse, compared with two catecholamine depletion using ␣-methyl-para-tyrosine patients during the diphenhydramine session. All patients (AMPT), an inhibitor of tyrosine hydroxylase, in patients returned to baseline scores after drug discontinuation. with SAD in natural summer remission. Nine drug-free Catecholamine depletion results in significant clinical patients with SAD by DSM-IV criteria, in summer relapse in patients with SAD in the untreated, summer- remission for at least eight weeks, completed a double-blind, remitted state. AMPT-induced depressive relapse may be a crossover study. Behavioral ratings and serum HVA and trait marker for SAD, and/or brain catecholamines may MHPG levels were obtained for 3-day sessions during play a direct role in the pathogenesis of SAD. which patients took AMPT or an active control drug, [Neuropsychopharmacology 25:S97–S101, 2001] diphenhydramine.The active AMPT session significantly © 2001 American College of Neuropsychopharmacology. reduced serum levels of HVA and MHPG compared with Published by Elsevier Science Inc. KEY WORDS: Seasonal affective disorder; Alpha-methyl- pattern, with full remission of symptoms (or a switch para-tyrosine; Catecholamines; Dopamine; Noradrenaline; into hypomania/mania) during spring/summer.
    [Show full text]